New heart device aims to zap away irregular rhythm
NCT ID NCT05462145
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new device called the Globe Pulsed Field System to treat people with atrial fibrillation (AF), a common heart rhythm problem. The device uses electrical pulses to destroy small areas of heart tissue causing the irregular rhythm. About 549 participants will be followed for 12 months to see if the procedure is safe and effective at preventing AF episodes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Globe Pulsed Field System (a device that uses electrical pulses to ablate heart tissue)
What this could lead to
If successful, this could provide a new, safer way to control atrial fibrillation and reduce symptoms without long-term medication.
What could go wrong
This is an early-stage study without a control group, so results may not confirm effectiveness. Risks include procedure-related complications like bleeding or heart rhythm issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beaumont Hospital
Royal Oak, Michigan, 48073, United States
-
Charité Campus Virchow Clinic
Berlin, Germany
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Doylestown Hospital
Doylestown, Pennsylvania, 18901, United States
-
Grandview Medical Center
Birmingham, Alabama, 35243, United States
-
Heart and Diabetes Center NRW
Bad Oeynhausen, Germany
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Johns Hopkins
Baltimore, Maryland, 21287, United States
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
-
Mercy Hospital
Miami, Florida, 33133, United States
-
Motol and Homolka University Hospital
Prague, Czechia
-
Mt. Sinai Hospital, Guggenheim Pavilion
New York, New York, 10029, United States
-
St. Bernards Medical Center
Jonesboro, Arkansas, 72401, United States
-
St. Vincent's Medical Center
Jacksonville, Florida, 32204, United States
-
St.Paul's Hospital
Vancouver, British Columbia, V6E 1M7, Canada
-
Sutter Health - California Pacific Medical Center
San Francisco, California, 94109, United States
-
Texas Cardiac Arrhythmia Research Foundation
Austin, Texas, 78705, United States
-
Westpfalz-Klinikum GmbH Kaiserslautern
Kaiserslautern, 67655, Germany